Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.

Benny O, Agarwal A, Alecock H, Subramani RG, Pawar A, Shams Z, Kermansaravi M, Pouwels S, Yang W, Obi CG, Cripps P, Tang A and 38 more

Show all authors

Gelber E, Lala A, Nadi K, Mahmoud A, Hammoda M, Al-Sarireh H, Egan R, Hanratty D, Drummond A, Caplin S, Harris D, Barry J, Beamish A, Al-Ardah M, Al-Sarireh B, Sum Ong SC, Hajibandeh S, Honey JR, Dababneh A, Ribordy V, Hautz WE, Jakob D, Patel B, Sprackling I, Ashabi A, Kambal A, Oviedo RJ, Parmar C, Mowbray N, Al Hadad M, Gawdat K, Hoffmann R, Hakky S, Al-Sarireh A, Nowak MA, Shikora S, Ahmed AR, Ahmad SJ

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]27 Mar 2026Cited by 1 (Europe PMC)

PMID41927408DOI10.1016/j.pan.2026.03.021PepBankPUB-41927408

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewSafety outcome
Across randomised trials of tirzepatide, acute pancreatitis was exceedingly rare (0.22%).
In plain wordsAcross trials of tirzepatide, acute pancreatitis was very rare (0.22%).
Peptide
Tirzepatide
Outcome
Not applicableAcute pancreatitis incidence
Study
n = 15,471
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Studied dose
5, 10 and 15 mg once weeklyAs given in this study (human).
Measurements
acute pancreatitis incidence
0.22%
pooled tirzepatide trials
Source sentences
Summary
Acute pancreatitis was exceedingly rare (0.22%).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) reporting outcomes from Tirzepatide 5, 10, and 15 mg once weekly were systematically reviewed.
Report a problemFND-4192740801
02HumanSystematic reviewSafety outcome
Across randomised trials, tirzepatide 10 mg did not differ from 5 mg in acute pancreatitis risk (RR 0.78).
In plain wordsAcross trials, tirzepatide 10 mg did not carry a different pancreatitis risk than 5 mg.
Peptide
Tirzepatide
Outcome
No significant changeAcute pancreatitis, 10 mg versus 5 mg
Study
n = 15,471
Comparator
Tirzepatide 5 mg
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Studied dose
5, 10 and 15 mg once weeklyAs given in this study (human).
Measurements
RR
0.78 ratio
10 mg vs 5 mg
Source sentences
Summary
10 mg vs 5 mg (RR 0.78, 95% CI 0.29-2.09)
2 context sentences(design, population, supporting numbers)
Summary · context
Across RCTs, acute pancreatitis with Tirzepatide is rare and shows no demonstrable dose-response between 5 and 15 mg.
Summary · context
Randomised controlled trials (RCTs) reporting outcomes from Tirzepatide 5, 10, and 15 mg once weekly were systematically reviewed.
Report a problemFND-4192740802
03HumanSystematic reviewSafety outcome
Across randomised trials, tirzepatide 15 mg did not differ from 5 mg in acute pancreatitis risk (RR 0.70).
In plain wordsAcross trials, tirzepatide 15 mg did not carry a different pancreatitis risk than 5 mg.
Peptide
Tirzepatide
Outcome
No significant changeAcute pancreatitis, 15 mg versus 5 mg
Study
n = 15,471
Comparator
Tirzepatide 5 mg
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Studied dose
5, 10 and 15 mg once weeklyAs given in this study (human).
Measurements
RR
0.7 ratio
15 mg vs 5 mg
Source sentences
Summary
15 mg vs 5 mg (RR 0.70, 0.27-1.82)
2 context sentences(design, population, supporting numbers)
Summary · context
Across RCTs, acute pancreatitis with Tirzepatide is rare and shows no demonstrable dose-response between 5 and 15 mg.
Summary · context
Randomised controlled trials (RCTs) reporting outcomes from Tirzepatide 5, 10, and 15 mg once weekly were systematically reviewed.
Report a problemFND-4192740803
04HumanSystematic reviewSafety outcome
Across randomised trials, tirzepatide 15 mg did not differ from 10 mg in acute pancreatitis risk (RR 1.13).
In plain wordsAcross trials, tirzepatide 15 mg did not carry a different pancreatitis risk than 10 mg.
Peptide
Tirzepatide
Outcome
No significant changeAcute pancreatitis, 15 mg versus 10 mg
Study
n = 15,471
Comparator
Tirzepatide 10 mg
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Studied dose
5, 10 and 15 mg once weeklyAs given in this study (human).
Measurements
RR
1.13 ratio
15 mg vs 10 mg
Source sentences
Summary
15 mg vs 10 mg (RR 1.13, 0.42-3.02)
2 context sentences(design, population, supporting numbers)
Summary · context
Across RCTs, acute pancreatitis with Tirzepatide is rare and shows no demonstrable dose-response between 5 and 15 mg.
Summary · context
Randomised controlled trials (RCTs) reporting outcomes from Tirzepatide 5, 10, and 15 mg once weekly were systematically reviewed.
Report a problemFND-4192740804
05HumanSystematic reviewSafety outcome
In generalised linear mixed models of tirzepatide trials, age and sex did not materially modify acute pancreatitis risk.
In plain wordsIn pooled tirzepatide trials, age and sex did not clearly change the pancreatitis risk.
Peptide
Tirzepatide
Outcome
No significant changeAge and sex as moderators of pancreatitis risk
Study
n = 15,471
Outcome group
Adverse events · Gastrointestinal
Studied dose
5, 10 and 15 mg once weeklyAs given in this study (human).
Source sentences
Summary
GLMMs yielded similar inferences; age and sex did not materially modify risk.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) reporting outcomes from Tirzepatide 5, 10, and 15 mg once weekly were systematically reviewed.
Report a problemFND-4192740805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.